-
Sunshine Biopharma’s Canadian subsidiary, Nora Pharma launches biosimilar drug, Niopeg
04 Jul 2025 10:53 GMT
… a pharmaceutical company offering and researching life-saving medicines in … to the reference biologic drug Neulasta (Pegfilgrastim). Like … colony-stimulating factor (filgrastim). It is indicated … small molecule for treatment of SARS Coronavirus infections …
-
Aurobindo Pharma shares in focus after European Commission nod for cancer drug Dazublys
03 Jul 2025 10:02 GMT
… April 2025 from the European Medicines Agency’s (EMA) … Committee for Medicinal Products for Human Use … reference drug Herceptin.
Dazublys is indicated for the treatment of … Dyrupeg (pegylated filgrastim) in April and Zefylti (filgrastim) in February. …
-
Global Chemotherapy-Induced Neutropenia Treatment Market To Reach $0.76 Billion By 2029 With A Growth Rate Of 5.3%
13 Jun 2025 15:33 GMT
… , and expanding oncology drug pipelines. Rising chemotherapy … , Novartis AG, Takeda Pharmaceutical Company Limited, Amgen Inc … treatment market. For example, Coherus BioSciences Inc. received FDA … Factor Therapy G-CSF: Filgrastim, Pegfilgrastim, Lenograstim
3 …
-
‘How was this missed for SO long?’ Woman, 32, reveals the signs of killer cancer doctors repeatedly ignored
30 Apr 2025 10:06 GMT
… to be repeatedly dismissed by doctors.
“I was turned away … the bone pain from the Filgrastim injections have been the hardest … body is responding to the treatment.
What is Hodgkin lymphoma?
…
For anyone facing pushback from doctors, Emma urged them to trust …
-
Human medicines European public assessment report (EPAR): Pelmeg, pegfilgrastim, Date of authorisation: 20/11/2018, Revision: 10, Status: Authorised
02 Apr 2025 23:01 GMT
… each cycle of chemotherapy (treatment with cancer medicines). Patients can inject themselves … package leaflet or contact your doctor or pharmacist.
How does Pelmeg … -colony-stimulating factor (G-CSF). Filgrastim works by encouraging the bone …
-
CuraTeQ Biologics received Marketing Authorization for Dyrupeg™, a pegylated filgrastim biosimilar
07 Apr 2025 13:40 GMT
… (EU) for Dyrupeg™, a pegylated filgrastim biosimilar, to CuraTeQ Biologics s … , the Committee for Medicinal Products (CHMP) of European Medicines Agency had adopted …
-
Global Neupogen Filgrastim Market Forecast 2025-2034: Analyzing Growth Drivers, Share, Segments, And Emerging Trends
18 Mar 2025 12:51 GMT
… demand for cost-effective neutropenia treatments.
oExpanded healthcare access in emerging … .
oA greater focus on personalized medicine.
oA growing elderly population.
… Neupogen Filgrastim market is categorized into the following segments:
1.By Drug …
-
Global Neutropenia Biologic Drug Treatment Market Forecast 2024-2033: Analyzing Growth Drivers, Market Share, and Trends
14 Nov 2024 12:15 GMT
… and clinical trial outcomes.
… Pharmaceutical Industries Ltd., Kyowa Kirin Co. Ltd., Tianjin CanSino Biotechnology … Drug Treatment Market Segmented?
1) By Drug Type: Filgrastim … Drug Treatment Market?
Neutropenia biologic drug treatment involves medications …
-
Human medicines European public assessment report (EPAR): Pelgraz Paediatric, pegfilgrastim, Status: Application withdrawn
28 Feb 2025 18:54 GMT
… , is a form of filgrastim, which is very similar … infections.
Filgrastim has been available in other medicines in the … In Pelgraz Paediatric and Neulasta, filgrastim has been ‘pegylated’ (attached … removal of filgrastim from the body, allowing the medicine to …
-
Filgrastim Market Set to Surge to $745.9 Million by 2030 at a 2.8% CAGR
26 Feb 2025 00:32 GMT
… biosimilar versions of filgrastim have made treatments more accessible and … Filgrastim Market Segmentation
The Filgrastim Market is segmented based on drug … Novartis
• Pfizer Inc.
• Teva Pharmaceutical Industries Ltd.
• Toksöz Group (Arven …
About
© 1995-2025